Rahway: Merck, known as MSD outside of the United States and Canada, has received conditional approval from the European ...

Merck’s Welireg receives European approval for two indications: Rahway, New Jersey Wednesday, February 19, 2025, 10:00 Hrs [IST] Merck, known as MSD outside of the United States ...

The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.

On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral ...

US pharma giant Merck & Co today announced that the European Commission (EC) has conditionally approved two indications for Welireg (belzutifan), its oral hypoxia-inducible factor-2 alpha (HIF-2α) ...

The EC has conditionally approved MSD's Welireg as a single agent for the treatment of adults with VHL disease and advanced ...

Merck (MRK) announced that the European Commission has conditionally approved WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, ...

The treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated, localized renal cell ...

Background: Von Hippel-Lindau (VHL) disease is an autosomal-dominant hereditary cancer syndrome. Currently, studies on tyrosine kinase inhibitor (TKI) therapy for VHL disease are scarce. In this study ...

Welireg is already approved by the FDA for the treatment of adults with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas ...

Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome characterized by poor survival. The effect of the involvement of each organ on survival remains unclear. Our study aimed to study the ...